Lexicon Pharmaceuticals (LXRX) Free Cash Flow (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Free Cash Flow data on file, last reported at -$14.7 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 66.35% year-over-year to -$14.7 million in Q1 2026; TTM through Mar 2026 was -$38.8 million, a 76.97% increase from a year earlier, with the FY2025 full-year figure at -$67.9 million, up 62.27% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$14.7 million, up from -$17.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for LXRX reached as high as $17.0 million in Q2 2025 and fell as low as -$55.1 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$30.3 million across 5 years, with a median of -$24.4 million in 2022.
• Across the five-year window, Free Cash Flow plunged 121.56% in 2023 and jumped 134.83% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$22.8 million in 2022, then slumped by 121.56% to -$50.5 million in 2023, then surged by 56.55% to -$22.0 million in 2024, then advanced by 21.54% to -$17.2 million in 2025, then advanced by 14.52% to -$14.7 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$14.7 million in Q1 2026, -$17.2 million in Q4 2025, and -$23.8 million in Q3 2025.